Applied DNA Sciences (Applied DNA Sciences) Cash-to-Debt

: 3.01 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Applied DNA Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.01.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Applied DNA Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Applied DNA Sciences's Cash-to-Debt or its related term are showing as below:

APDN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23 Med: No Debt Max: No Debt
Current: 3.01

During the past 13 years, Applied DNA Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.23. And the median was No Debt.

APDN's Cash-to-Debt is ranked better than
61.37% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.44 vs APDN: 3.01

Applied DNA Sciences Cash-to-Debt Historical Data

The historical data trend for Applied DNA Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Applied DNA Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

0.36

3.32

No Debt

5.78

Applied DNA Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																No Debt	8.35	7.94	5.78	3.01

Competitive Comparison

For the Diagnostics & Research subindustry, Applied DNA Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied DNA Sciences Cash-to-Debt Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Applied DNA Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Applied DNA Sciences's Cash-to-Debt falls into.

Applied DNA Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Applied DNA Sciences's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7.152	/	(0.499	+	0.739)
	=	5.78

Applied DNA Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.359	/	(0.51	+	0.607)
	=	3.01

Applied DNA Sciences (NAS:APDN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Applied DNA Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Applied DNA Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied DNA Sciences (Applied DNA Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Applied DNA Sciences Inc (NAS:APDN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

UDJP:Germany

Address

50 Health Sciences Drive, Stony Brook, New York, NY, USA, 11790

Website

https://www.adnas.com

Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

Executives

Clay Shorrock	officer: Chief Legal Officer	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Scott L Anchin	director	16990 GOLDENTOP ROAD, SUITE A, SAN DIEGO CA 92127
William W Montgomery	10 percent owner	34211 SEAVEY LOOP RD., EUGENE OR 97405
Judith Murrah	officer: Chief Information Officer	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Beth Jantzen	officer: Chief Financial Officer	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov A Shamash	director
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
John Iii Bitzer	director	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Joseph D. Ceccoli	director	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Elizabeth M. Ferguson	director	50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Charles S. Ryan	director	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
James A Hayward	director, officer: Chief Executive Officer	C/O 25 HEALTH SCIENCES DRIVE, SUITE 113, NEW YORK NY 11790
Karol Gray	officer: Chief Financial Officer	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Ming-hwa Benjamin Liang	officer: Strategic Tech. Dev. Officer	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov Shamash	director	100 ENGINEERING, STATE UNIVERSITY OF NY, STONE BROOK NY 117942200